4-甲基-3-苄氧基苄醇 | 916792-34-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-甲基-3-苄氧基苄醇
• 英文名称: (3-benzyloxy-4-methyl-phenyl)methanol
• 英文别名: [3-(Benzyloxy)-4-methylphenyl]methanol；(4-methyl-3-phenylmethoxyphenyl)methanol
• CAS: 916792-34-2
• 化学式: C₁₅H₁₆O₂
• 分子量: 228.291
• InChiKey: GBVCRKCGVJJDFL-UHFFFAOYSA-N

物化性质

• 沸点：
  380.0±32.0 °C(Predicted)
• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-甲基-3-苄氧基苄醇 在 manganese dioxide silica gel 、 ethyl acetate n-hexane 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以to give the title compound (0.39 g)的产率得到3-苄氧基-4-甲基苯甲醛
  参考文献：
  名称：

  (Aza)indole derivative and use thereof for medical purposes

  摘要：

  本发明提供了一种化合物，其具有利尿作用或类似作用，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及以下通式（I）所代表的（氮）吲哚衍生物，其具有黄嘌呤氧化酶抑制活性，并可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂、其前药或盐。在式（I）中，T代表硝基或氰基等；环J代表芳基或杂芳基等；Q代表羧基或5-四唑基等；Y代表H、OH、NH2、卤素、硝基、烷基、烷氧基等；X1、X2和X3独立地代表CR2或N；R1和R2独立地代表卤素、氰基、卤代烷基、A-D-E-G、—N(-D-E-G)2等，在该式中，A代表单键、O、S等；D和G独立地代表可选取代的烷基、环烷基、杂环烷基、芳基、杂芳基等；E代表单键、O、S、COO、SO2等。

  公开号：

  US08003647B2
• 作为产物：
  描述：

  3-羟基-4-甲基苯甲酸甲酯 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 4-甲基-3-苄氧基苄醇
  参考文献：
  名称：

  Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

  摘要：

  这项发明提供了具有一般公式的新化合物： 其中R1、R2、R3、R4、R5和R6如本文所述，包括这些化合物的组合物和使用这些化合物的方法。

  公开号：

  US20150210682A1

文献信息

• [EN] NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES DIHYDROQUINOLIZINONES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015113990A1

  公开（公告）日：2015-08-06

  The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.

  这项发明提供了具有一般式（I）的新化合物，其中R1、R2、R3、R4、R5和R6如本文所述，包括这些化合物的组合物以及在治疗乙型肝炎病毒方面使用这些化合物的方法。
• (Aza)indole derivative and use thereof for medical purposes
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US08003647B2

  公开（公告）日：2011-08-23

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetrazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, —N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

  本发明提供了一种化合物，其具有利尿作用或类似作用，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及以下通式（I）所代表的（氮）吲哚衍生物，其具有黄嘌呤氧化酶抑制活性，并可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂、其前药或盐。在式（I）中，T代表硝基或氰基等；环J代表芳基或杂芳基等；Q代表羧基或5-四唑基等；Y代表H、OH、NH2、卤素、硝基、烷基、烷氧基等；X1、X2和X3独立地代表CR2或N；R1和R2独立地代表卤素、氰基、卤代烷基、A-D-E-G、—N(-D-E-G)2等，在该式中，A代表单键、O、S等；D和G独立地代表可选取代的烷基、环烷基、杂环烷基、芳基、杂芳基等；E代表单键、O、S、COO、SO2等。
• (aza)indole derivative and use thereof for medical purposes
  申请人：Shimizu Kazuo

  公开号：US08466152B2

  公开（公告）日：2013-06-18

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, —N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

  本发明提供了化合物，其作为预防或治疗与异常血清尿酸水平相关的疾病的代理，具有利尿作用或类似作用。本发明涉及以下一般式（I）所代表的（氮）吲哚衍生物，具有黄嘌呤氧化酶抑制活性，可用作预防或治疗与血清尿酸水平异常相关的疾病的代理、其前药或其盐。在公式（I）中，T代表硝基、氰基等；环J代表芳基或杂环芳基等；Q代表羧基或5-四氮唑基等；Y代表H、OH、NH2、卤素、硝基、烷基、烷氧基等；X1、X2和X3独立地代表CR2或N；R1和R2独立地代表卤素、氰基、卤代烷基、A-D-E-G、-N（-D-E-G）2等，在公式中，A代表单键、O、S等；D和G独立地代表可选择的取代基的烷基、环烷基、杂环烷基、芳基、杂环芳基等；E代表单键、O、S、COO、SO2等。
• AROMATIC RING COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150045378A1

  公开（公告）日：2015-02-12

  Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  提供了一种具有GPR40激动剂活性的芳香环化合物。式（I）所表示的化合物：其中每个符号如说明中所述，或其盐具有GPR40激动剂活性，并且可用作预防或治疗糖尿病等疾病的药剂。
• Aromatic ring compound
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US09181186B2

  公开（公告）日：2015-11-10

  Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  提供了一种具有GPR40激动剂活性的芳香环化合物。式（I）所表示的化合物：其中每个符号如描述中所述，或其盐具有GPR40激动剂活性，并且可用作预防或治疗糖尿病等疾病的药剂。